Introduction: The Challenges of Type 2 Diabetes
Type 2 diabetes mellitus (T2DM) is a chronic disease characterized by high blood glucose levels, resulting from impaired insulin production or the body's inability to use it effectively. T2DM carries a high risk of developing atherosclerotic cardiovascular disease, heart failure, and renal failure, making it one of the leading causes of morbidity and mortality worldwide [3, 8]. Effective management of glucose levels and the prevention of complications are key objectives in T2DM treatment. Over the past decades, physicians have gained access to new classes of drugs that not only effectively lower blood sugar but also possess additional cardio- and nephroprotective properties.
Evolution of Treatment: From Traditional to Innovative Approaches
Traditionally, T2DM treatment began with lifestyle modifications and the use of oral glucose-lowering drugs (OGLDs). A study conducted in China showed that the most commonly used OGLDs were insulin secretagogues (e.g., sulfonylureas and glinides), metformin, alpha-glucosidase inhibitors, and thiazolidinediones [2]. However, these drugs do not always provide long-term glycemic control and do not always prevent the progression of complications. Patients on monotherapy with sulfonylureas or glinides often required changes to their treatment regimen [2].
Modern approaches to T2DM therapy have significantly expanded, offering new classes of drugs that act through various mechanisms and provide more comprehensive protection for the body.
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): Powerful Control and Heart Protection
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injectable medications that mimic the action of the natural hormone GLP-1. They stimulate insulin production in a glucose-dependent manner, suppress glucagon secretion, slow gastric emptying, and promote weight loss. Since 2005, several GLP-1 agonists have been approved, including liraglutide, albiglutide, dulaglutide, and lixisenatide, as well as a once-weekly form of exenatide. Semaglutide is also under FDA review [1].
These drugs have demonstrated significant benefits in reducing glucose levels and body weight. Moreover, numerous clinical trials and meta-analyses have confirmed their ability to reduce the risk of atherosclerotic cardiovascular events and cardiovascular mortality in patients with T2DM [3, 6, 8]. The mechanisms of action of GLP-1 agonists are similar to the endocrine changes following bariatric surgery, which highlights their potential in achieving diabetes remission [7].
SGLT2 Inhibitors (SGLT2i): Protecting the Heart, Kidneys, and Reducing Hospitalization Risk
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a relatively new class of oral medications that act in the kidneys by increasing glucose excretion in the urine. This leads to a decrease in blood glucose levels, as well as a reduction in blood pressure and body weight.
One of the most significant findings was the proof that SGLT2 inhibitors provide powerful protection for the cardiovascular system and kidneys. They significantly reduce the risk of heart failure and hospitalizations related to it, an effect observed in both patients with and without diabetes [3, 8]. Studies have shown that SGLT2 inhibitors, along with GLP-1 agonists, have proven cardiovascular benefits in patients with T2DM, especially after acute coronary syndrome [6]. These drugs are now included in guidelines for the treatment of cardiovascular diseases, including heart failure and chronic kidney disease [8].
Glucokinase Activators (GKAs): A New Perspective on Glycemic Control
Glucokinase activators (GKAs) are a class of antidiabetic drugs designed to regulate blood sugar levels and improve pancreatic beta-cell function. Achieving glycemic control and maintaining the activity of functional beta-cells remain an unmet medical need in T2DM [4].
Significant progress in GKA development is aimed at addressing the limitations of previous generations. For example, dorzagliatin, a dual GKA acting on both the liver and the pancreas, has successfully completed two phase III trials, demonstrating favorable results. The hepatoselective GKA TTP399 also shows clinically significant results with minimal side effects [4]. These new GKAs could become an important addition to the arsenal of T2DM treatments.
Dual and Triple Agonists: A Comprehensive Approach to Metabolic Disorders
The growing prevalence of T2DM and obesity requires new, more effective approaches. Currently, new dual and triple agonists are being actively developed that simultaneously target multiple receptors, such as GLP-1, glucose-dependent insulinotropic polypeptide (GIP), glucagon, and growth differentiation factor 15 (GDF15) [5].
These new agents not only improve metabolic parameters but may also have cardioprotective and anti-inflammatory effects [5]. Their mechanisms of action are similar to GLP-1 agonists and GIP/GLP-1 dual agonists, which, like bariatric surgery, can contribute to achieving T2DM remission [7]. These multi-agonists promise more comprehensive management of both diabetes and comorbid obesity.
The Future of Treatment: From Remission to Personalization
Modern medications are changing the T2DM treatment landscape, offering not only glycemic control but also significant benefits for the cardiovascular system and kidneys [8]. The concept of pharmacological remission of T2DM is emerging, where glucose and HbA1c levels below the diagnostic threshold for diabetes are achieved using highly effective, weight-reducing glucose-lowering drugs. This opens new perspectives in disease management, especially considering that these treatments can safely achieve lower glucose concentrations than those used to define drug-free remission [7].
The interaction between cardiology and diabetology is becoming increasingly important for optimizing cardiovascular disease prevention and heart failure treatment in patients with T2DM [3]. The future of T2DM treatment will likely include even more personalized approaches based on individual patient needs, comorbidities, and risk profiles, with an emphasis on drugs that provide maximum protection against complications.
References
- 1. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists. https://pubmed.ncbi.nlm.nih.gov/28991932/
- 2. China type 2 diabetes treatment status survey of treatment pattern of oral drugs users. https://pubmed.ncbi.nlm.nih.gov/24809622/
- 3. The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management. https://pubmed.ncbi.nlm.nih.gov/32402065/
- 4. New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes Treatment. https://pubmed.ncbi.nlm.nih.gov/38203742/
- 5. Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management. https://pubmed.ncbi.nlm.nih.gov/40817831/
- 6. Glucose-Lowering Drugs with Proven Cardiovascular Benefit Following Acute Coronary Syndrome in Patients with Type 2 Diabetes: Treatment Gaps and Outcomes. https://pubmed.ncbi.nlm.nih.gov/39337027/
- 7. Challenging the Consensus Statement: Is It Time to Recognise Pharmacological Remission of Type 2 Diabetes? https://pubmed.ncbi.nlm.nih.gov/41852334/
- 8. Now and the Future: Medications Changing the Landscape of Cardiovascular Disease and Heart Failure Management. https://pubmed.ncbi.nlm.nih.gov/40507711/
The information provided in this article is for reference purposes only and should not be used for self-diagnosis or self-treatment. Always consult a qualified physician for an accurate diagnosis and an individualized treatment plan.